ERSP deflates Leading Edge's enhancement claims
This article was originally published in The Tan Sheet
Executive Summary
The Electronic Retailing Self-Regulation Program recommends Leading Edge Marketing modify or discontinue some efficacy claims for its male enhancement products. ERSP in a Sept. 15 report also recommends Leading Edge disclose more clearly on its BetterSexMall.com website the relationship between the products, reviewers and the firm. Following an anonymous challenge, ERSP recommends the company modify claims related to stamina, erection size and "more powerful orgasm" for its products VigRX, VigRX Plus and VigRX Oil. No human studies were conducted with the products, and Leading Edge's data did not adequately support the claims, says the Council of Better Business Bureaus division. ERSP notes the Earth City, Mo.-based firm modified its website, but did not adequately disclose that it owns BetterSexMall.com, which purports to be independent. ERSP notes three Leading Edge-affiliated websites with customer testimonials do not comply with 2009 Federal Trade Commission guideline requirement to disclose typical results from use of the product (1"The Tan Sheet" Oct. 12, 2009). The company said it plans to comply
You may also be interested in...
FTC Testimonial Guide Moves Past "Results Not Typical," Enters Blog Era
The Federal Trade Commission raised the bar on substantiation and disclosure of "typical results" in testimonials and endorsements in advertising, in a revised guide released Oct. 5
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.